1. Introduction {#sec1-ijms-18-00540}
===============

Thyroid cancer is common type of malignant tumor, affecting approximately 1% of the total population. Thyroid cancer manifests as several common subtypes, including papillary thyroid carcinoma (PTC), follicular carcinoma (FC), medullary carcinoma (MC), poorly differentiated carcinoma (PDC), and anaplastic carcinoma (AC). Notably, the cellular origin, clinical manifestation, metastatic pattern, and clinical prognosis have been reported to differ depending on the subtype \[[@B1-ijms-18-00540]\].

In the field of cancer research, autophagy, defined as the lysosomal degradation of cellular components, has recently received considerable attention. Autophagy plays an important role in homeostasis through the removal of dysfunctional or damaged cellular components and recycling of necessary cellular components \[[@B2-ijms-18-00540],[@B3-ijms-18-00540],[@B4-ijms-18-00540],[@B5-ijms-18-00540]\]. Among the various proteins involved in the autophagy process, the following markers are commonly used to evaluate autophagic activity: light chain (LC) 3, which participates in elongation and contributes to autophagosome formation \[[@B6-ijms-18-00540],[@B7-ijms-18-00540],[@B8-ijms-18-00540]\]; p62, a scaffold protein that transfers ubiquitinated proteins to the autophagosome \[[@B9-ijms-18-00540],[@B10-ijms-18-00540]\]; and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), a mitochondrial autophagy (mitophagy) regulator \[[@B11-ijms-18-00540]\].

Given its role in homeostasis, autophagy acts as a double-edged sword in cancers. The high metabolic demands of highly aggressive malignant tumors cannot be satisfied by angiogenesis and/or aerobic glycolysis alone, leading to activation of the alternative metabolic pathway in which cytoplasmic components are recycled via autophagy to provide a source of cellular energy \[[@B12-ijms-18-00540],[@B13-ijms-18-00540]\]. However, unrestrained autophagy eventually leads to cell death following the progressive consumption of cellular constituents \[[@B14-ijms-18-00540],[@B15-ijms-18-00540]\]. Accordingly, autophagy plays roles in both tumor suppression and progression, and the autophagy status has been linked to the tumor subtype in various types of cancer \[[@B16-ijms-18-00540],[@B17-ijms-18-00540],[@B18-ijms-18-00540],[@B19-ijms-18-00540],[@B20-ijms-18-00540]\].

In human thyroid cancer, the autophagy status may similarly vary according to the tumor subtype. However, previous studies regarding the expression of autophagy-related proteins in thyroid cancer have not yielded clear results. Therefore, in this study, we investigated the expression of LC3A, LC3B, p62, and BNIP-3, the major components of autophagy, in human thyroid carcinomas, as well as the implications of these expression patterns.

2. Results {#sec2-ijms-18-00540}
==========

2.1. Basal Characteristics of Thyroid Cancer {#sec2dot1-ijms-18-00540}
--------------------------------------------

In this study, we included 555 thyroid cancer cases, including 342 cases of PTC (other subtypes: FC, 112; MC, 70; PDC, 23; and AC, 8). The basal characteristics of the PTC cases are listed in [Table S1](#app1-ijms-18-00540){ref-type="app"}. This group comprised 302 cases of conventional type and 40 cases of follicular variant disease, and 236 of the 342 cases (69.0%) harbored the BRAF V600E mutation. The FC group comprised 99 cases of minimally invasive type and 13 cases of widely invasive type disease, for which the basal characteristics are listed in [Table S2](#app1-ijms-18-00540){ref-type="app"}. The basal characteristics of MC, PDC, and AC are presented in [Table S3](#app1-ijms-18-00540){ref-type="app"}.

2.2. Expression of Autophagy-Related Proteins in Thyroid Cancer {#sec2dot2-ijms-18-00540}
---------------------------------------------------------------

We next evaluated the expression of autophagy-related proteins in thyroid cancers and observed significant differences in tumoral LC3A (*p* \< 0.001), stromal LC3A (*p* \< 0.001), LC3B (*p* \< 0.001), and BNIP-3 (*p* = 0.016) expression patterns with respect to thyroid cancer subtype. Tumoral LC3A and LC3B expression was highest in MC, whereas stromal LC3A expression was higher in AC and PTC. BNIP-3 expression was negative in both MC and AC ([Figure 1](#ijms-18-00540-f001){ref-type="fig"} and [Table 1](#ijms-18-00540-t001){ref-type="table"}).

We further evaluated the expression of autophagy-related proteins in PTCs according to the histologic subtype and BRAF V600E mutation status. We found that tumoral LC3A (*p* = 0.026), LC3B (*p* = 0.007), and p62 (*p* \< 0.001) expression differed significantly according to the histologic subtype. Higher tumoral LC3A, LC3B, and p62 expressions were observed in conventional type tumors relative to follicular variant tumors. In addition, the expression of all autophagy-related proteins differed significantly according to the BRAF V600E mutation status (*p* \< 0.05); specifically, the BRAF V600E mutation was associated with higher expression levels of all autophagy-related proteins ([Table 2](#ijms-18-00540-t002){ref-type="table"} and [Figure 2](#ijms-18-00540-f002){ref-type="fig"}). In contrast, in an analysis of follicular neoplasms, no significant differences were observed in the expression of autophagy-related proteins between FA and FC or between FC, minimally invasive and FC, widely invasive ([Table 3](#ijms-18-00540-t003){ref-type="table"} and [Table 4](#ijms-18-00540-t004){ref-type="table"}).

2.3. Correlation Among the Expressions of Autophagy-Related Proteins {#sec2dot3-ijms-18-00540}
--------------------------------------------------------------------

The results of the correlation analysis of the expression of LC3A, LC3B, p62, and BNIP3 showed significant correlation between LC3A (T) and LC3A (S), LC3B, p62 and BNIP3 (*r* = −0.233, 0.255, 0.132, 0.138 respectively; all *p* \< 0.001); between LC3A (S) and LC3B (*r* = 0.120; *p* \< 0.001); between LC3A (S) and p62 (*r* = 0.108; *p* \< 0.001); between LC3B and p62 (*r* = 0.253; *p* \< 0.001); between LC3B and BNIP3 (*r* = 0.058; *p* = 0.038); and between p62 and BNIP3 (*r* = 0.180; *p* \< 0.001) ([Table 5](#ijms-18-00540-t005){ref-type="table"}).

2.4. Correlations between Clinicopathologic Factors and Autophagy-Related Protein Expression in Thyroid Cancers {#sec2dot4-ijms-18-00540}
---------------------------------------------------------------------------------------------------------------

Furthermore, we evaluated the correlations between clinicopathologic factors and the expression of autophagy-related proteins in thyroid cancers. In PTCs, p62 expression differed depending on the stromal type (*p* = 0.002), whereas the proportion of tumors with positive p62 expression was higher among desmoplastic and inflammatory type tumors than among normal-like and sclerotic type tumors. BNIP-3 negativity was associated with capsular invasion in FC (*p* = 0.001), and p62 negativity was associated with lymph node metastasis in MC (*p* = 0.006) ([Figure 3](#ijms-18-00540-f003){ref-type="fig"}).

2.5. Impact of the Expression of Autophagy-Related Proteins on the Prognosis of Patients with Thyroid Cancer {#sec2dot5-ijms-18-00540}
------------------------------------------------------------------------------------------------------------

Finally, a logistic regression analysis was performed to evaluate the role of autophagy-related protein expression on prognosis among patients with thyroid cancer. In the univariate analysis, LC3B positivity associated with a shorter disease-free survival (*p* = 0.011). Although autophagy-related protein expression did not have a significant impact on prognosis among the total PTC group, LC3B negativity associated with a shorter disease-free survival among patients with BRAF V600E mutation-positive PTC (*p* = 0.024) ([Figure 4](#ijms-18-00540-f004){ref-type="fig"} and [Table 6](#ijms-18-00540-t006){ref-type="table"}).

3. Discussion {#sec3-ijms-18-00540}
=============

In this study, we investigated the expression of autophagy-related proteins in thyroid cancers and confirmed the existence of different expression patterns according to disease subtype. For example, we observed significantly higher levels of tumoral LC3A and LC3B expression in MC, a finding that was corroborated by a previous study in which higher expression levels of autophagy-related molecules, such as beclin-1 and LC3B, were observed in a MC cell line \[[@B21-ijms-18-00540]\]. According to that earlier study, sporadic type and hereditary type MCs differed with respect to the autophagy status, and higher expression levels of autophagy-related molecules were observed in the former \[[@B21-ijms-18-00540]\]. The different autophagy statuses observed in MC, compared to other types of thyroid cancer, might be attributable to differences in the expression of micro-RNAs (miRNAs), which have been reported to regulate autophagic activity in MC \[[@B21-ijms-18-00540]\]. In addition, differences in miRNA expression profiles have been observed among different thyroid cancer subtypes \[[@B22-ijms-18-00540]\]. Therefore, autophagic activity may differ as a result of distinct miRNA expression patterns, although this will require additional studies.

In our analysis of PTC, we observed differences in autophagy-related protein expression according to the BRAF V600E mutation status. Specifically, higher expression levels of all autophagy-related proteins were observed in PTCs with the BRAF V600E mutation, compared to those without the BRAF V600E mutation. In support of this finding, previous studies have observed an association between the BRAF V600E mutation and increased autophagy \[[@B23-ijms-18-00540],[@B24-ijms-18-00540]\]. This association may be attributed to multiple factors. First, chronic ER stress may play a mechanistic role. Following activation of the IRE1/ASK1/JNK and TRB3 pathways via BRAF V600E-mediated p38 activation, Bcl-XL/Bcl-2 phosphorylation, induced by active JNK, and Akt/mTOR axis inhibition, mediated by TRB3, lead to increased autophagic activity \[[@B24-ijms-18-00540]\]. Second, long non-coding RNAs (lncRNAs) may also play a mechanistic role. For example, an increase in the LC3-II/LC3-I that was mediated by BRAF-activated lncRNA was found to induce autophagy in a previous study \[[@B23-ijms-18-00540]\].

Our results further demonstrated a high level of stromal LC3A expression in PTC. Previously, stromal LC3A expression was also observed in breast cancer \[[@B18-ijms-18-00540]\], similar to the findings of this study. The expression of autophagy-related proteins in tumor stroma has been attributed to a "reverse Warburg" effect, wherein a metabolic interaction exists between breast cancer cells and stromal cells. According to this theory, glycolysis, mitochondrial dysfunction, and increased autophagy activity are induced in stromal cells by reactive oxygen species produced by breast cancer cells. Ketone bodies and lactate, the by-products of glycolysis in stromal cells, enter cancer cells and facilitate the production of ATP through oxidative phosphorylation \[[@B25-ijms-18-00540],[@B26-ijms-18-00540],[@B27-ijms-18-00540]\]. Therefore, according to the reverse Warburg effect, autophagic activity would increase in stromal cells, which corresponds with the increased expression of LC3A and LC3B in PTC tumor stroma. In this context, cancer-associated fibroblasts that express reduced levels of caveolin-1 serve as tumor cell-interacting stromal cells \[[@B28-ijms-18-00540],[@B29-ijms-18-00540]\]. In a previous study of thyroid cancer, the reported proportion of caveolin-1-negative stroma was 78.9% \[[@B30-ijms-18-00540]\], suggesting that the reverse Warburg effect may describe the situation in PTC. However, further studies are needed to clarify this potential mechanism.

We note that one limitation of our study was the use of immunohistochemistry (IHC) to detect autophagy-related proteins (beclin-1, LC3A, and LC3B) as an indicator of autophagic activity. Because autophagy is a dynamic, multi-step process, a static measure of autophagy activity (e.g., IHC) may yield inaccurate results. Namely, as the autophagy-related proteins LC3A and LC3B are autophagosome components, the increased expression of these proteins could be interpreted as an increase in the number of autophagosomes and, therefore, in autophagic activity. However, an increased number of autophagosomes might also result from delayed degradation. Therefore, an analysis of autophagy flux, which indicates changes in autophagic stages, would yield a more accurate measurement of autophagic activity \[[@B10-ijms-18-00540]\]. However, it was impossible to evaluate autophagy flux in our IHC study of paraffin-embedded tumor samples.

Clinically, the results of our study imply that autophagy regulation should be considered as a potential cancer therapeutic target. Recent evidence suggests that treatment with autophagy inhibitors could inhibit the growth of various tumors \[[@B31-ijms-18-00540],[@B32-ijms-18-00540],[@B33-ijms-18-00540],[@B34-ijms-18-00540]\]. Specifically, autophagy inhibition might provide insights into the treatment of MC, which expresses high levels of autophagy markers and for which an effective target therapy is not currently available.

4. Materials and Methods {#sec4-ijms-18-00540}
========================

4.1. Patient Selection and Study Design {#sec4dot1-ijms-18-00540}
---------------------------------------

This study included patients with diagnosed PTC who underwent surgery at Severance Hospital between January 2012 and December 2013, as well as patients diagnosed with other thyroid cancer subtypes following surgery at Severance Hospital between January 2000 and December 2014. Patients who received preoperative chemotherapy were excluded. The study protocol was approved by the Institutional Review Board of Yonsei University Severance Hospital (8 November 2016; 4-2016-0832).

All cases of thyroid cancer were reviewed retrospectively by a single thyroid pathologist (Ja Seung Koo) via a histologic review of hematoxylin and eosin (H&E)-stained slides. Clinicopathologic data were obtained from the patients' medical records and included the age at diagnosis, disease recurrence, metastasis status, current status, and duration of follow-up. The tumor size, location (right or left lobe), extent (confined to the thyroid parenchyma or with extrathyroidal spread), and number of metastatic lymph nodes were also determined from the histologic review of tumor slides and surgical pathology reports.

4.2. Tissue Microarray {#sec4dot2-ijms-18-00540}
----------------------

Representative areas on (H&E)-stained slides were selected, and corresponding spots were marked on the surfaces of matching paraffin blocks. Three-millimeter sized tissue cores were extracted by using a manual tissue arrayer from the selected areas and placed into a 6 × 5 recipient block. More than two tissue cores were extracted from each case to minimize extraction bias. Each tissue core was assigned a unique tissue microarray location number that was linked to a database containing other clinicopathologic data.

4.3. Immunohistochemistry {#sec4dot3-ijms-18-00540}
-------------------------

The antibodies used for (IHC) are listed in [Table 7](#ijms-18-00540-t007){ref-type="table"}. All IHC analyses were performed using formalin-fixed, paraffin-embedded tissue sections. Briefly, 5-μm-thick sections were obtained with a microtome, transferred onto adhesive slides, and dried at 62 °C for 30 min. After incubation with primary antibodies, immunodetection was performed using biotinylated anti-mouse immunoglobulin followed by peroxidase-labeled streptavidin, using a labeled streptavidin biotin kit with 3,3′-diaminobenzidine chromogen as the substrate. The primary antibody incubation step was omitted from the negative control. A positive control tissue was used per the manufacturer's recommendation. Slides were counterstained with Harris hematoxylin.

4.4. Interpretation of Immunohistochemical Staining {#sec4dot4-ijms-18-00540}
---------------------------------------------------

Immunohistochemical marker expression was visualized using light microscopy. Stained slides were evaluated semi-quantitatively according to a previously reported method \[[@B35-ijms-18-00540]\]. Tumor and stromal cell staining were assessed using the following scoring system: 0, negative or weak immunostaining in \<1% of the tumor/stroma; 1, focal expression in 1%--10% of the tumor/stroma; 2: positive staining in 11%--50% of the tumor/stroma; and 3: positive staining in 51%--100% of the tumor/stroma. The entire tumor area was subjected to assessment, and a score of ≥2 was defined as positive. BRAF V600E staining was considered positive when more than 20% tumor cells were positive, as previously described \[[@B36-ijms-18-00540]\].

4.5. Statistical Analysis {#sec4dot5-ijms-18-00540}
-------------------------

Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp. Released 2012. Armonk, NY, USA). For determinations of statistical significance, Student's *t*-test and Fisher's exact test were used for continuous and categorical variables, respectively. The correlation between the expression of GLS1, GDH, and ASCT was analyzed using Kendall's tau. To analyze data with multiple comparisons, a corrected *p*-value and the Bonferroni multiple comparison procedure were applied. Statistical significance was set at a *p*-value \< 0.05. Kaplan--Meier survival curves and log-rank statistics were used to evaluate the time to tumor recurrence and overall survival. A Cox proportional hazards model was used for the multivariate regression analysis.

5. Conclusions {#sec5-ijms-18-00540}
==============

In conclusion, our combined data indicate that the expression of autophagy-related proteins in thyroid cancers differs according to the subtype and, among PTCs, the BRAF V600E mutation status. These findings, which corroborate the results of earlier studies, may lead to improvements and developments in the field of target therapy for thyroid cancer.
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ijms-18-00540-t001_Table 1

###### 

Expression of autophagy-related proteins according to histologic thyroid cancer subtype.

  Parameters   Total *n*= 555 (%)   PTC *n*= 342 (%)   FC *n*= 112 (%)   MC *n*= 70 (%)   PDC *n*= 23 (%)   AC *n* = 8 (%)   *p*-Value
  ------------ -------------------- ------------------ ----------------- ---------------- ----------------- ---------------- -------------
  LC3A (T)                                                                                                                   **\<0.001**
  Negative     421 (75.9)           294 (86.0)         99 (88.4)         0 (0.0)          20 (87.0)         8 (100.0)        
  Positive     134 (24.1)           48 (14.0)          13 (11.6)         70 (100.0)       3 (13.0)          0 (0.0)          
  LC3A (S)                                                                                                                   **\<0.001**
  Negative     359 (64.7)           167 (48.8)         99 (88.4)         70 (100.0)       21 (91.3)         2 (25.0)         
  Positive     196 (35.3)           175 (51.2)         13 (11.6)         0 (0.0)          2 (8.7)           6 (75.0)         
  LC3B                                                                                                                       **\<0.001**
  Negative     283 (51.0)           146 (42.7)         99 (88.4)         14 (20.0)        20 (87.0)         4 (50.0)         
  Positive     272 (49.0)           196 (57.3)         13 (11.6)         56 (80.0)        3 (13.0)          4 (50.0)         
  P62                                                                                                                        0.220
  Negative     221 (39.8)           134 (39.2)         53 (47.3)         24 (34.3)        6 (26.1)          4 (50.0)         
  Positive     334 (60.2)           208 (60.8)         59 (52.7)         46 (65.7)        17 (73.9)         4 (50.0)         
  BNIP-3                                                                                                                     **0.016**
  Negative     494 (89.0)           297 (86.8)         100 (89.3)        70 (100.0)       19 (82.6)         8 (100.0)        
  Positive     61 (11.0)            45 (13.2)          12 (10.7)         0 (0.0)          4 (17.4)          0 (0.0)          

PTC: papillary thyroid carcinoma; FC: follicular carcinoma; MC: medullary carcinoma; PDC: poorly differentiated carcinoma; AC: anaplastic carcinoma; T: tumoral; S: stromal. Bold indicates statistically significant (*p* \< 0.05).

ijms-18-00540-t002_Table 2

###### 

Expression of autophagy-related proteins according to histologic papillary thyroid carcinoma subtype.

  Parameters   Total *n* = 342 (%)   Histologic Subtype   *p*-Value   BRAF V600E Mutation Status   *p*-Value                 
  ------------ --------------------- -------------------- ----------- ---------------------------- ------------ ------------ -------------
  LC3A (T)                                                            **0.026**                                              **0.002**
  Negative     294 (86.0)            255 (84.4)           39 (97.5)                                100 (94.3)   194 (82.2)   
  Positive     48 (14.0)             47 (15.6)            1 (2.5)                                  6 (5.7)      42 (17.8)    
  LC3A (S)                                                            0.133                                                  **0.031**
  Negative     167 (48.8)            143 (47.4)           24 (60.0)                                61 (57.5)    106 (44.9)   
  Positive     175 (51.2)            159 (52.6)           16 (40.0)                                45 (42.5)    130 (55.1)   
  LC3B                                                                **0.007**                                              **\<0.001**
  Negative     146 (42.7)            121 (40.1)           25 (62.5)                                68 (64.2)    78 (33.1)    
  Positive     196 (57.3)            181 (59.9)           15 (37.5)                                38 (35.8)    158 (66.9)   
  p62                                                                 **\<0.001**                                            **\<0.001**
  Negative     134 (39.2)            105 (34.8)           29 (72.5)                                72 (67.9)    62 (26.3)    
  Positive     208 (60.8)            197 (65.2)           11 (27.5)                                34 (32.1)    174 (73.7)   
  BNIP-3                                                              0.327                                                  **\<0.001**
  Negative     297 (86.8)            260 (86.1)           37 (92.5)                                105 (99.1)   192 (81.4)   
  Positive     45 (13.2)             42 (13.9)            3 (7.5)                                  1 (0.9)      44 (18.6)    

T: tumoral; S: stromal. Bold indicates statistically significant (*p* \< 0.05).

ijms-18-00540-t003_Table 3

###### 

Expression of autophagy-related proteins in follicular neoplasms.

  Parameters   Total *n* = 265 (%)   FA *n* = 153 (%)   FC *n* = 112 (%)   *p*-Value
  ------------ --------------------- ------------------ ------------------ -----------
  LC3A (T)                                                                 0.300
  Negative     240 (90.6)            141 (92.2)         99 (88.4)          
  Positive     25 (9.4)              12 (7.8)           13 (11.6)          
  LC3A (S)                                                                 0.278
  Negative     227 (85.7)            128 (83.7)         99 (88.4)          
  Positive     38 (14.3)             25 (16.3)          13 (11.6)          
  LC3B                                                                     0.221
  Negative     226 (85.3)            127 (83.0)         99 (88.4)          
  Positive     39 (14.7)             26 (17.0)          13 (11.6)          
  p62                                                                      0.185
  Negative     138 (52.1)            85 (55.6)          53 (47.3)          
  Positive     127 (47.9)            68 (44.4)          59 (52.7)          
  BNIP-3                                                                   0.946
  Negative     237 (89.7)            137 (89.5)         100 (89.3)         
  Positive     28 (10.6)             16 (10.5)          12 (10.7)          

FA: follicular adenoma; FC: follicular carcinoma; T: tumoral; S: stromal.

ijms-18-00540-t004_Table 4

###### 

Expression of autophagy-related proteins according to histologic follicular carcinoma (FC) subtype.

  Parameters   Total *n* = 112 (%)   FC, Minimally Invasive Type *n* = 99 (%)   FC, Widely Invasive Type *n* = 13 (%)   *p*-Value
  ------------ --------------------- ------------------------------------------ --------------------------------------- -----------
  LC3A (T)                                                                                                              0.646
  Negative     99 (88.4)             88 (88.9)                                  11 (84.6)                               
  Positive     13 (11.6)             11 (11.1)                                  2 (15.4)                                
  LC3A (S)                                                                                                              1.000
  Negative     99 (88.4)             87 (87.9)                                  12 (92.3)                               
  Positive     13 (11.6)             12 (12.1)                                  1 (7.7)                                 
  LC3B                                                                                                                  0.651
  Negative     99 (88.4)             11 (84.6)                                  88 (88.9)                               
  Positive     13 (11.6)             2 (15.4)                                   11 (11.1)                               
  p62                                                                                                                   0.616
  Negative     53 (47.3)             46 (46.5)                                  7 (53.8)                                
  Positive     59 (52.7)             53 (53.5)                                  6 (46.2)                                
  BNIP-3                                                                                                                0.354
  Negative     100 (89.3)            87 (87.9)                                  13 (100.0)                              
  Positive     12 (10.7)             12 (12.1)                                  0 (0.0)                                 

T: tumoral; S: stromal.

ijms-18-00540-t005_Table 5

###### 

Correlation among the expressions of autophagy-related proteins.

  Parameters                LC3A (T)      LC3A (S)      LC3B          p62
  ------------------------- ------------- ------------- ------------- -------------
  LC3A (T)                                                            
  Correlation coefficient   \-            \-            \-            \-
  *p*-value                 \-            \-            \-            \-
  LC3A (S)                                                            
  Correlation coefficient   −0.233        \-            \-            \-
  *p*-value                 **\<0.001**   \-            \-            \-
  LC3B                                                                
  Correlation coefficient   0.255         0.120         \-            \-
  *p*-value                 **\<0.001**   **\<0.001**   \-            \-
  p62                                                                 
  Correlation coefficient   0.132         0.108         0.253         \-
  *p*-value                 **\<0.001**   **\<0.001**   **\<0.001**   \-
  BNIP3                                                               
  Correlation coefficient   0.138         0.029         0.058         0.180
  *p*-value                 **\<0.001**   0.297         **0.038**     **\<0.001**

T: tumoral; S: stromal. Bold indicates statistically significant (*p* \< 0.05).

ijms-18-00540-t006_Table 6

###### 

Univariate analysis of the influences of autophagy-related protein expression on disease-free and overall survival among patients with papillary thyroid cancer (log-rank test).

  Parameter   Number of Patients /Recurrence/Death   Disease-Free Survival   Overall Survival                    
  ----------- -------------------------------------- ----------------------- ------------------ ---------------- -------
  LC3A (T)                                                                   0.717                               0.327
  Negative    294/16/14                              106 (104--109)                             108 (106--110)   
  Positive    48/2/4                                 106 (100--111)                             103 (97--109)    
  LC3A (S)                                                                   0.923                               0.216
  Negative    167/9/6                                107 (103--110)                             109 (107--111)   
  Positive    175/9/12                               105 (102--108)                             104 (101--107)   
  LC3B                                                                       0.257                               0.805
  Negative    146/10/7                               105 (101--109)                             108 (105--111)   
  Positive    196/8/11                               108 (105--110)                             107 (105--110)   
  p62                                                                        0.643                               0.140
  Negative    134/8/4                                105 (101--109)                             108 (106--111)   
  Positive    208/10/14                              107 (104--110)                             106 (103--109)   
  BNIP-3                                                                     0.804                               0.055
  Negative    297/16/13                              106 (104--109)                             108 (106--110)   
  Positive    45/2/5                                 107 (101--113)                             102 (95--110)    

CI: confidence interval; T: tumoral; S: stromal.

ijms-18-00540-t007_Table 7

###### 

Sources, clones, and dilutions of antibodies used for immunohistochemistry.

  Antibody     Clone        Dilution   Company
  ------------ ------------ ---------- --------------------------
  LC3A         EP1528Y      1:100      Abcam, Cambridge, UK
  LC3B         Polyclonal   1:100      Abcam, Cambridge, UK
  p62          SQSTM1       1:100      Abcam, Cambridge, UK
  BNIP-3       Ana40        1:100      Abcam, Cambridge, UK
  BRAF V600E   VE1          1:50       Ventana, Tucson, AZ, USA
